Under the license, Ferring will be able to use the full OmniAb platform including OmniRat, OmniMouse, OmniFlic, and OmniChicken to discover fully human mono- and
bispecific antibodies.
Our recently published data on
bispecific antibodies reinforces the significant potential of this new therapeutic approach," commented Professor Ugur Sahin, founder and CEO of BioNTech.
With biopharma's evolving pipeline of novel protein therapeutics, such as
bispecific antibodies, multimeric proteins and Fc-fusion proteins, CHO cells are being pushed to their productivity limits in drug development and manufacturing.
Beyond these five
bispecific antibodies, Merck will have further rights to replace, as well as to add to these antibodies using F-stars bispecific antibody platform.
This conference will present data and case studies on key topics such as antibody drug conjugates,
bispecific antibodies and overcoming the blood-brain barrier.
But at the same time that monoclonal antibodies have hogged the spotlight, their distant cousins,
bispecific antibodies, have been floating around.
Their topics include the humanization of antibodies, affinity maturation approaches for antibody lead optimization, antibody expression from bacteria to transgenic animals, the design and application of immunoconjugates for cancer therapy, and dual-targeting
bispecific antibodies as new therapeutic modalities for cancer.
Bispecific antibodies are considered to be more potent and effective than other antibody therapeutics.
DVD-Ig, which stands for dual-variable-domain immunoglobulin, is also known as
bispecific antibodies.
Bispecific antibodies also can be generated as small, antigen-binding variable domains (Fv) that improve the pharmacokinetic properties (localization and clearance) of the primary targeting agent, while also binding to a versatile, bivalent, peptide-hapten carrying an imaging or therapeutic radionuclide.
Antibody-dependent enhancement of dengue virus infection mediated by
bispecific antibodies against cell surface molecules other than Fc-gamma receptor.
Morris Plains, NJ) announced the issuance of a new United States Patent 6,399,068, which covers therapeutic
bispecific antibodies for the treatment of cancers, especially B-cell malignancies, such as non-Hodgkin's lymphoma.
